PB1864: BRUIN CLL-321: A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF PIRTOBRUTINIB VS INVESTIGATOR’S CHOICE OF IDELALISIB+RITUXIMAB OR BENDAMUSTINE+RITUXIMAB IN BTKI PRETREATED CLL/SLL (TRIAL IN PROGRESS)

Detalles Bibliográficos
Autores principales: Sharman, J. P., Jurczak, W., Coombs, C. C., Hill, M., Wang, D., Ku, N. C., Guntur, A., Shahda, S., Leow, C. C., Ghia, P., Mato, A. R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Publication Only
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429640/
http://dx.doi.org/10.1097/01.HS9.0000850308.96349.64

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429640/
http://dx.doi.org/10.1097/01.HS9.0000850308.96349.64

Ejemplares similares